RTW Biotech Opportunities Ltd Provides Monthly Valuation Update
Why we think this is neutral
This RNS announcement is a routine monthly valuation update and factsheet for the RTW Biotech Opportunities Ltd investment fund. It does not contain any of the mandatory news types that would require a more detailed analysis.
Key Points
- NAV per share increased 0.2% in June 2025
- Fund has delivered +8.8% annualised NAV per share performance since launch
- Top holdings include Corxel, Avidity, Akero, Kailera, and UroGen
Summary
The investment fund provides its monthly valuation update, reporting a 0.2% increase in net asset value per share for June 2025.
RTW Biotech Opportunities Ltd (LSE: RTW) has released its monthly factsheet and second quarter update as at 30 June 2025. The fund's unaudited net asset value attributable to its ordinary shares was US$1.70 per share, an increase of 0.2% from the previous month. The fund has delivered an annualised NAV per ordinary share performance of +8.8% since launch in October 2019.
Key Dates
9 September 2025
Annual General Meeting
GENERAL UPDATE